Clinical Trials Browser

Bulbo-Spinal Atrophy, X-Linked × 1 year × Clear all

Bulbo-Spinal Atrophy, X-Linked

NCT04708431 2026-05-19

Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivity

Recruiting

650 enrolled

Androgen-Insensitivity Syndrome, Bulbo-Spinal Atrophy, X-Linked

NCT03437941 2026-05-15

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Terminated

39 enrolled 43 charts

Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT06764485 2026-05-06

rechARge

Phase 3 Recruiting

960 enrolled

Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT07336446 2026-05-01

ANDROMEDA

Phase 1/2 Recruiting

300 enrolled

Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Phase 2 Completed

57 enrolled

Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT06365788 2026-04-01

ABBICAR

Phase 2 Recruiting

53 enrolled

Breast

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

NCT04090528 2025-12-05

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Phase 2 Active not recruiting

60 enrolled 10 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02294461 2025-10-24

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Phase 3 Completed

395 enrolled 25 charts

Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Clinical Trials

TulmiSTAR-02

Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivity

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

rechARge

ANDROMEDA

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

ABBICAR

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants